Bio-link Australia Pty. Ltd.


Please find below a list of selected recent news and press releases from Bio-Link, our clients and the industry. Please select a specific news list for each source from the buttons on the left hand side.

2nd May 2017 – Bio-Link Engaged by GenoFAB

Bio-Link has been engaged by GenoFAB to assist with the commercialisation of iVectors™, a new generation of intelligently designed, high-performance, custom protein expression vectors that have been optimized for upstream and downstream processing to rescue difficult-to-manufacture proteins.

To learn more about this partnering opportunity, please click here.

28th March 2017 – Oncology Venture – APO010 approved for testing in phase II multiple myeloma trial

Oncology Venture’s immuno-oncology drug APO010, a first-in-class FAS-ligand, will be tested in a subset of Multiple Myeloma patients identified as likely responders by the Drug Response Predictor (DRPTM) precision medicine technology. Read Full Story Here

oncology venture logo-1

14th February 2017 – Neural Diagnostics Awarded A$2.2M in CRC-P Grant

Neural Diagnostics Pty Ltd, a Melbourne-based medtech developer, have been awarded $2.2M in a 2nd round CRC-P grant to develop their EVestG™ technology for medical applications in the field of head trauma. The project is a collaboration with GE Healthcare and Monash University that is expected to be completed in 3 years at a total expenditure of $8.1M.

EVestG™ (ElectroVestibuloGraphy) is a novel technology and medical device that enables a simple, non-invasive test for the objective and accurate classification of a range of neurological diseases, including Alzheimer’s, Parkinson’s, autism spectrum disorder, bipolar disorder, depression, Ménière’s disease, schizophrenia and concussion. Potential applications for EVestG™ range from streamlining development of CNS drugs to clinical diagnostics to workplace safety and more.

CRC-Ps are a stream of the Australian CRC Programme in which a small group of collaborators work on a single, short term, industry-identified and industry-led collaborative research project to develop a product, service or process that will solve problems for business and deliver tangible outcomes.

Neural Diagnostics have engaged Bio-Link to facilitate business development and strategic partnerships for EVestG™.

Neural Diagnostics

31st January 2017 – Bio-Link Engaged by Neural Diagnostics

Bio-Link has been engaged by Neural Diagnostics for the development of ElectroVestibuloGraphy (EVestG™), a novel medical device for the classification of neurological diseases. Bio-Link is seeking commercial partner(s) for licensing and commercial development of EVestG™ in the fields of clinical diagnostics, medical devices and drug development.

To learn more about this partnering opportunity, please click here.

Neural Diagnostics

29th August 2016 – Bio-Link Engaged by ShenQi Pharmaceutical

Bio-Link has been engaged by ShenQi Pharmaceutical (ShenQi), a subsidiary of ShenQi Group (GuiZhou, China), to scout for a strategic partner able to contribute advanced assisted reproductive technologies to a new business opportunity in the Chinese market.

To learn more about this partnering opportunity, please click here.